Senseera

Executive Summary

Senseera is an Israeli biotech company pioneering an AI-driven chromatin liquid biopsy platform (cfChIP-seq) that profiles cell-free chromatin from as little as 1 mL of plasma. By measuring over one million genomic regulatory features, it generates high-resolution cell-state gene-expression biomarkers, enabling non-invasive diagnosis, monitoring, and drug development across liver disease, oncology, immunology, and metabolic disorders. Unlike traditional liquid biopsies that focus on mutations or methylation, Senseera's approach captures real-time epigenetic and transcriptional activity, offering a dynamic view of disease states. This technology has the potential to transform early detection, treatment selection, and therapeutic response monitoring, particularly in areas like hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). Founded in 2020 and headquartered in Tel Aviv, Senseera has raised $7.1 million to date and operates as a platform company with broad applications. Its AI-powered platform is designed to accelerate biomarker discovery and drug development partnerships. Senseera's technology is well-positioned to address unmet needs in precision medicine, especially for complex diseases where tissue biopsies are impractical. With ongoing validation studies and interest from pharmaceutical partners, the company could play a key role in advancing personalized healthcare. The platform's versatility across multiple therapeutic areas provides significant upside for investors seeking exposure to next-generation liquid biopsy technologies.

Upcoming Catalysts (preview)

• Q4 2026Pharmaceutical partnership for liver disease biomarker development40% success
• Q1 2027Publication of clinical validation data in a peer-reviewed journal70% success
• Q1 2027Series A financing round ($20M+)50% success